Three-drug combo for advanced solid tumors resistant to immunotherapy
Part of Brain & nervous system, Cancer, Skin clinical trials.
This trial tests a combination of three drugs (tislelizumab, bevacizumab, and capecitabine) in people with advanced solid tumors that have stopped responding to other treatments. It has specific groups for certain breast cancers and for people with brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 21 years old.
- You have an advanced or metastatic solid tumor that has not responded or cannot be treated with standard therapies.
- You are able to do daily activities (fully active or only limited in heavy physical work).
- If you have triple-negative breast cancer, it must be PD-L1-negative and you haven't had treatment for advanced disease.
- If you have brain metastases, they must be stable and not causing major symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
This trial is testing a combination of three drugs (utidelone, tirelizumab, and bevacizumab) for people with advanced or metastatic triple-negative breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if this combination can shrink tumors or slow the disease.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.